Sanatela is a pioneering biotechnology clinic dedicated to advancing the field of cancer treatment through innovative research and development. Specializing in personalized oncology, they have developed the Sanatela™ Matrix, an advanced biomaterial designed to significantly enhance the screening of both new and existing therapies against cancer stem cells, particularly in leukemia. This revolutionary product utilizes a natural 3D biological tissue derived from human umbilical cords, known as Wharton’s Jelly, which is decellularized and bioengineered to attract and isolate cancer cells from a patient’s blood sample. By creating a tailored treatment strategy in the lab, oncologists can determine the most effective therapies for individual patients, ultimately aiming for a potential cure.
The clinic's unique value proposition lies in its commitment to individualized therapy. By culturing leukemia samples on the Sanatela Matrix, clinicians can safely test a variety of cancer treatments, allowing for a thorough evaluation of their efficacy before administration. This approach not only streamlines the decision-making process for oncologists but also significantly reduces the trial-and-error aspect of cancer treatment. With an established partnership with a Contract Manufacturing Organization (CMO) in a state-of-the-art clean room facility, Sanatela is poised to expand its operations, making its innovative Matrix available for external research, clinical trials, and expanded access submissions. As it continues to push the boundaries of cancer therapy, Sanatela stands at the forefront of transforming patient outcomes in the fight against leukemia.
